You have looked at the column "after 1st dose". If you instead look at the column "after 2nd dose" you can identify correctly that all patients receiving Pfizer had a minimum antibody level higher than the maximum of that for Sinovac, and that the mean antibody level after Pfizer is dramatically greater than that for Sinovac.if we check the detail, we see from 93 participants of Pfizer vaccine, the PRNT50 value evenly spread between 0 to 320, which means any sampling of 12 of them could result in different results, yet Sinovac sample was merely 12 participants, far from significance.
that being said, we agree on the fact that there's effeciancy difference, just some sidenote.
on the other hand, I'm curious that if the PRNT50 data is so important, why there's such huge discrepancy between mRNA vac takers?
The sample size of 12 is small, but the effect size is so vast (mean antibody level of 269 with Pfizer after 2nd dose compared to 27 for Sinovac) that this still produces robust data. The associated t-statistic on a two-sample unpaired t-test is 24.99 with a corresponding p value <0.00001.
I.e., the chance of seeing a difference this large or greater due to chance alone is borderline impossible.